Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Recurrence 1Pancreatic Neoplasms 1Liver Neoplasms 1Conversion Disorder 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

Bevacizumab 23Sorafenib 20Doxorubicin 14Gemcitabine 11durvalumab 10Oxaliplatin 10Fluorouracil 10Cisplatin 10Capecitabine 9Nivolumab 8pembrolizumab 6Sunitinib 6tremelimumab 5atezolizumab 5Radiofrequency Ablation 5Neoadjuvant Therapy 5Leucovorin 5lenvatinib 4aldesleukin 4Thalidomide 4Radiotherapy 4Radiosurgery 4Everolimus 4Erlotinib Hydrochloride 4Drug Therapy 4Carboplatin 4toripalimab 3regorafenib 3camrelizumab 3apatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liver Neoplasms × Hepatectomy × Clear all
NCT05471674 2023-02-01

Neoadjuvant Anti-PD1 in HCC

The University of Hong Kong

Phase 2 Completed
20 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡